Table 4.

Subtyping assay for RBD-IgG and titration for N-IgG in the phase 1 trial.

	Baseline			Day 28			Day 42
Items	5 μg group (N = 24)	10 μg group (N = 24)	Placebo group (N = 12)	5 μg group (N = 23)	10 μg group (N = 24)	Placebo group (N = 12)	5 μg group (N = 23)	10 μg group (N = 23)	Placebo group (N = 12)
IgG1 GMT	5.0 (5.0–5.0)	5.0 (5.0–5.0)	5.0 (5.0–5.0)	34.4 (25.2–47.0)	42.4 (30.0–59.8)	5.0 (5.0–5.0)	30.5 (25.6–37.1)	31.4 (22.5–43.9)	5.0 (5.0–5.0)
IgG2 GMT	5.0 (5.0–5.0)	5.0 (5.0–5.0)	5.0 (5.0–5.0)	5.2 (4.8–5.5)	5.5 (4.6–6.5)	5.0 (5.0–5.0)	5.0 (5.0–5.0)	5.3 (4.7–6.0)	5.0 (5.0–5.0)
IgG3 GMT	5.0 (5.0–5.0)	5.0 (5.0–5.0)	5.0 (5.0–5.0)	5.8 (4.9–7.0)	6.7 (5.2–8.5)	5.0 (5.0–5.0)	5.2 (4.8–5.5)	5.8 (4.8–7.1)	5.0 (5.0–5.0)
IgG4 GMT	5.0 (5.0–5.0)	5.0 (5.0–5.0)	5.0 (5.0–5.0)	12.0 (9.0–16.0)	17.3 (12.1–24.7)	5.0 (5.0–5.0)	9.4 (7.0–12.7)	12.7 (9.2–17.5)	5.0 (5.0–5.0)
N-IgG GMT	11.9 (7.2–19.7)	10.0 (6.7–14.9)	6.3 (4.7–8.4)	90.3 (50.4–161.7)	358.8 (208.9–616.2)	5.6 (4.7–6.7)	122.0 (72.2–206.2)	394.7 (240.6–647.8)	6.3 (4.5–8.9)

Data are GMT (95% CI). CI: Confidence interval; GMT: Geometric mean titer; N-IgG: Antibody directed against nucleoprotein; N: Number of participants included in each treatment group for the per-protocol immunogenicity analysis; RBD-IgG: Antibody directed against the receptor-binding domain.